KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ionis Pharmaceuticals (IONS) Common Equity (2016 - 2025)

Historic Common Equity for Ionis Pharmaceuticals (IONS) over the last 17 years, with Q3 2025 value amounting to $618.0 million.

  • Ionis Pharmaceuticals' Common Equity fell 671.75% to $618.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $618.0 million, marking a year-over-year decrease of 671.75%. This contributed to the annual value of $588.4 million for FY2024, which is 5215.21% up from last year.
  • Per Ionis Pharmaceuticals' latest filing, its Common Equity stood at $618.0 million for Q3 2025, which was down 671.75% from $631.7 million recorded in Q2 2025.
  • Ionis Pharmaceuticals' Common Equity's 5-year high stood at $771.7 million during Q4 2021, with a 5-year trough of $263.7 million in Q2 2024.
  • For the 5-year period, Ionis Pharmaceuticals' Common Equity averaged around $537.9 million, with its median value being $582.7 million (2021).
  • Its Common Equity has fluctuated over the past 5 years, first tumbled by 6697.33% in 2021, then soared by 13956.34% in 2025.
  • Over the past 5 years, Ionis Pharmaceuticals' Common Equity (Quarter) stood at $771.7 million in 2021, then dropped by 25.77% to $572.9 million in 2022, then plummeted by 32.5% to $386.7 million in 2023, then skyrocketed by 52.15% to $588.4 million in 2024, then increased by 5.03% to $618.0 million in 2025.
  • Its last three reported values are $618.0 million in Q3 2025, $631.7 million for Q2 2025, and $475.7 million during Q1 2025.